PetMed Express Shakes Up Leadership Amid Stock Surge and Governance Overhaul

Introduction to PETMED EXPRESS INC

PETMED EXPRESS INC (NASDAQ: PETS), also known as 1-800-PetMeds, is an online pharmacy specializing in prescription and non-prescription medications, nutritional supplements, and health products for dogs, cats, and horses. Founded in 1996 and headquartered in Delray Beach, Florida, the company serves customers through its e-commerce platform (1800petmeds.com) and a toll-free call center, coordinating prescriptions directly with veterinarians.

Corporate Structure and Workforce

As of 2025, PETMED EXPRESS INC employs between 201 and 500 staff members, reflecting a mid-sized enterprise capable of combining personalized service with scalable operations. The organization is licensed to dispense pet medications in all 50 states, supported by a team of pharmacists and customer-care specialists. Community engagement is integral to its culture: employees participate in partnerships with animal rescues such as Tri-County Animal Rescue and sports organizations like the Florida Panthers to host adoption and fundraising events.

Pet pharmacy by Patrick Shaun

Recent Management Changes

On August 12, 2025, the company announced the resignations of Chief Executive Officer Sandra Campos and Chief Financial Officer Robyn D’Elia.

• Leslie C.G. Campbell, Chair of the Board, assumed the role of Interim CEO.
• Douglas Krulik, Chief Accounting Officer, became Interim Principal Financial Officer.
  The board has initiated a search for permanent successors. Under the terms of their separation agreements dated August 11, 2025, both departing executives will receive 13 months of salary continuation and accelerated vesting of restricted stock units as part of their agreements.

On October 20, 2025, PETMED EXPRESS INC appointed James LaCamp, a former audit partner at Deloitte, to its Board of Directors. Effective October 30, Mr. LaCamp will chair the Audit Committee, qualifying as an “audit committee financial expert” under SEC guidelines. This appointment follows the addition of four independent directors since 2024, reflecting the company's ongoing governance evaluation.

Financial and Strategic Overview

Trading on NASDAQ under the ticker PETS, the stock price closed at $2.26 on December 10, 2025, representing a 27.68% increase for the day, with a volume of 2,988,691 shares. The company’s strategy centers on direct-to-consumer distribution, leveraging its website and call center to provide competitive pricing on brand-name and generic pet medications. By coordinating prescription fulfillment with veterinarians, PETMED EXPRESS INC positions itself as both a partner and competitor to traditional veterinary clinics.

E-commerce capabilities are complemented by ongoing digital partnerships. In April 2022, the company entered into a collaboration with Vetster to expand virtual veterinary consultations, enhancing customer convenience and prescription authorization.

Market Position and Industry Context

PETMED EXPRESS INC operates within the online pet pharmacy segment of the broader pet health market, which includes veterinary clinics, brick-and-mortar pharmacies, and emerging telehealth providers. The company’s early entry as a mail-order pharmacy in 1996 established brand recognition. Competitive advantages include a licensed pharmacy network, experienced pharmacists, and community outreach initiatives that support customer loyalty. The company's regulatory history, including settlements with state pharmacy boards in the early 2000s and the dismissal of class-action lawsuits in 2005 and 2018, has led to continued focus on compliance frameworks and internal controls, further supported by recent audit committee enhancements.

tl;dr

On August 12, 2025, PETMED EXPRESS INC’s CEO and CFO resigned, triggering interim leadership assignments and a search for successors. The stock (PETS) increased 27.68% to $2.26 on December 10, 2025. On October 20, 2025, James LaCamp joined the board as Audit Committee Chair to enhance financial governance. The company continues to expand direct-to-consumer and telehealth capabilities while reinforcing its board composition.